CSL (OTCMKTS:CSLLY) Rating Increased to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of CSL (OTCMKTS:CSLLY) to a strong-buy rating in a research note released on Thursday,Zacks.com reports.

CSL Trading Up 0.4 %

Shares of OTCMKTS:CSLLY opened at $86.16 on Thursday. CSL has a one year low of $83.31 and a one year high of $109.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97. The firm has a 50 day simple moving average of $89.07 and a 200 day simple moving average of $96.47.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.